Congress urges FDA to revisit abortion pill safety—without naming the studies
H.Res. 803 — Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes. · Filed by John Rose (R-TN) · 11 cosponsors · Introduced Oct 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This resolution urges the FDA to re-examine the safety of medication abortion drugs (mifepristone and misoprostol) and release a public safety review, citing claims that independent studies show complication rates 22 times higher than FDA-reported figures. The resolution frames this as a response to regulatory changes that expanded access to these drugs by mail and without in-person requirements, and expresses concern about state abortion restrictions being undermined.
Why we flagged it
The resolution is a non-binding urging that frames a politically contentious medication (abortion drugs) as a safety concern, citing disputed complication-rate claims. It is functionally a political messaging vehicle designed to pressure the FDA to revisit an approved drug class, not a routine safety inquiry.
What the text implies
- If the FDA complies, a new safety review could delay or restrict access to medication abortion, effectively implementing abortion restrictions through regulatory process rather than legislation—circumventing direct legislative debate.
- The resolution cites a single claim ('22 times higher' complication rate) without naming the independent studies, making it difficult to verify the scientific basis and suggesting selective citation of research.
The full analysis lists 4 implications of this text.
Who it affects
The resolution itself is non-binding and merely urges FDA review—it does not change law or policy directly. However, it reflects a political effort to restrict access to a legal medication.